Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169026 · ClinicalTrials.gov registry record · Phase 4
Alcoholism and Schizophrenia: Effects of Clozapine
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00169026: Clinical Trial Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00169026 is a Phase 4 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00169026, a Phase 4 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have greater efficacy in reducing alcohol use than other antipsychotic medications.
Interventions
- DRUG Clozapine versus typical (conventional) and atypical antipsychotic medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 1999-05 |
| Est. Completion | 2004-01 |
| Phase | Phase 4 |
Why NCT00169026 stopped before completion
NCT00169026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Clozapine versus typical (conventional) and atypical antipsychotic medications is the first listed.
NCT00169026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00169026 about?
NCT00169026 is a clinical study titled "Alcoholism and Schizophrenia: Effects of Clozapine". The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have greater efficacy in reducing alcohol use than other antipsychotic medications.
What is the current status of trial NCT00169026?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 1999-05. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00169026?
The interventions under investigation include: Clozapine versus typical (conventional) and atypical antipsychotic medications (DRUG).
Who is sponsoring clinical trial NCT00169026?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00169026's enrollment target sits among peer trials
64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia